Diffuse large B-cell lymphoma (DLBCL)

This article was last reviewed and updated on April 3, 2019

by Philip Berardi, MD PhD FRCPC

Quick facts:

  • Diffuse large B-cell lymphoma (DLBCL) is a cancer that comes from immune cells called lymphocytes.

  • It is the most common type of lymphoma to affect adults.

  • Diffuse large B-cell lymphoma is an aggressive cancer that can spread quickly if not treated.

The immune system

Your immune system is made up of many different kinds of cells and each play an important role protecting your body from infections and helping you heal after an injury. Unlike other types of organs, your immune system is spread throughout your body. Most immune cells are found in small organs called lymph nodes. Lymph nodes are located throughout your body. Large numbers of immune cells can also be found in the blood, skin, gastrointestinal tract, and bones. 

What is diffuse large B-cell lymphoma?

Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma to affect adults. It is a disease that can affect people of any age, but is more common in older adults (greater than 65 years old). This disease is slightly more common in men.


Diffuse large B-cell lymphoma is a cancer that comes from a type of immune cell called a lymphocyte. Because lymphocytes are normally found throughout your body, DLBCL can start almost anywhere in your body. Lymphocytes are a type of white blood cell that normally plays an important role in protecting you from infections.


The symptoms of DLBCL include a new lump or mass somewhere in the body, weight loss, fatigue, or unexplained sweating during the night.


The diagnosis of DLBCL is usually made after your doctor removes a small piece of tissue in a procedure called a biopsy.


Grade is a word pathologists use to describe how different the cancer cells look compared to normal lymphocytes. When examined under the microscope, the cancer cells in DLBCL are much larger than normal lymphocytes. They also usually have large nucleoli. For these reasons, DLBCL is considered a high-grade lymphoma.


DLBCL is an aggressive tumour which means the cancer cells can grow and spread quickly to other lymph nodes and organs in your body. For this reason, your doctor will probably recommend starting treatment right away.

Transformation from a low-grade lymphoma

Other less aggressive or low-grade types of lymphoma can change over time into DLBCL.  Pathologists call this type of change a transformation.


Low-grade lymphomas that can turn into DLBCL include:

  • Follicular lymphoma

  • Nodal and extranodal marginal zone lymphoma

  • Small lymphocytic lymphoma/Chronic lymphocytic leukemia

  • Lymphoplasmacytic lymphoma

Exactly how and why this change occurs is still not entirely understood, but it is thought to be related to many different factors. Some of these factors include gene mutations in the cancer cells themselves. Others believe that there are changes to our immune system that allow lymphoma cells to grow more quickly and transform into high-grade disease.

Whatever the cause, a low-grade lymphoma that transforms to a high-grade lymphoma behaves more aggressively. There are usually some different treatment options to consider at the time of lymphoma transformation. These can be discussed with your doctor. The goal is to make sure that your treatment plan suits your personal situation. This means that your treatment plan may be slightly different than someone else you know with the same disease.

Pattern of growth

Pattern of growth describes the way the cancer cells are grouped together when examined under the microscope. Diffuse large B-cell lymphoma typically forms a diffuse growth pattern of medium to large size cells. This means the large abnormal cells are spread over a relatively large area. As the tumour grows, it can replace the surrounding normal tissue or organ. The damage caused to normal tissue contributes to the symptoms you may be experiencing.


Unlike the less aggressive or low-grade lymphomas, DLBCL is usually more invasive which means the cancer cells can grow beyond the tissue where the tumour started and into neighbouring tissues or organs. If the tumour is large enough it can prevent nearby organs from functioning normally.

Immunohistochemistry is a test that allows pathologists to learn more about the types of proteins made by specific cells. Cells that produce a protein are called positive or reactive. Cells that do not produce a protein are called negative or non-reactive.

Immunohistochemistry is routinely performed on tumours that look like DLBCL to confirm the diagnosis and to exclude other diseases that have a similar look under the microscope.


Diffuse large B-cell lymphoma typically shows the following immunohistochemistry results:


  • CD20 – Positive.

  • PAX5 – Positive.

  • BCL2 – Positive (Occasionally negative).

  • BCL6 – Positive.

  • CD10 – Positive or negative.

  • MUM1 – Positive or negative.

  • CD23 – Negative.

  • CD3 – Negative.

  • CD5 – Negative.

  • Cyclin D1 – Negative.


Tumours that are positive for CD10 are called germinal center B-cell (GCB) type. In contrast, tumours that are negative for CD10 and positive for MUM1 are called non-germinal center B-cell (non-GCB) type.

  • Facebook
  • Twitter

Copyright 2017 MyPathologyReport.ca

For more information about this site, contact us at info@mypathologyreport.ca.

Disclaimer: The articles on MyPathologyReport are intended for general informational purposes only and they do not address individual circumstances. The articles on this site are not a substitute for professional medical advice, diagnosis or treatment and should not be relied on to make decisions about your health. Never ignore professional medical advice in seeking treatment because of something you have read on the MyPathologyReport site. The articles on MyPathologyReport.ca are intended for use within Canada by residents of Canada only.

Droits d'auteur 2017 MyPathologyReport.ca
Pour plus d'informations sur ce site, contactez-nous à info@mypathologyreport.ca.
Clause de non-responsabilité: Les articles sur MyPathologyReport ne sont destinés qu’à des fins d'information et ne tiennent pas compte des circonstances individuelles. Les articles sur ce site ne remplacent pas les avis médicaux professionnels, diagnostics ou traitements et ne doivent pas être pris en compte pour la prise de décisions concernant votre santé. Ne négligez jamais les conseils d'un professionnel de la santé à cause de quelque chose que vous avez lu sur le site de MyPathologyReport. Les articles sur MyPathologyReport.ca sont destinés à être utilisés au Canada, par les résidents du Canada uniquement.